Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Quest Diagnostics (NY:DGX)

208.66 -1.59 (-0.76%)
Streaming Delayed Price Updated: 1:50 PM EST, Mar 3, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Quest Diagnostics

< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
News headline image
Looking Into Quest Diagnostics's Recent Short Interest ↗
 
Via Benzinga
News headline image
Decoding 7 Analyst Evaluations For Quest Diagnostics ↗
 
Via Benzinga
News headline image
Uber To Rally Over 33%? Here Are 10 Top Analyst Forecasts For Monday ↗
 
Via Benzinga
News headline image
What Analysts Are Saying About Quest Diagnostics Stock ↗
 
Via Benzinga
News headline image
Diagnostic Giants Labcorp, Roche To Ramp Up Testing Capacity Amid Global Concerns Over New Mpox Strain ↗
Labcorp considers boosting its mpox testing capacity as the WHO declares a global health emergency. Companies like Roche and Quest Diagnostics are also monitoring demand and expanding testing... 
Via Benzinga
News headline image
Uncovering Dividend Opportunities with NYSE:DGX. ↗
Analyzing QUEST DIAGNOSTICS INC (NYSE:DGX)'s Dividend Potential. 
Via Chartmill
News headline image
5 Analysts Assess Quest Diagnostics: What You Need To Know ↗
 
Via Benzinga
News headline image
Cracking The Code: Understanding Analyst Reviews For Quest Diagnostics ↗
 
Via Benzinga
News headline image
How Is The Market Feeling About Quest Diagnostics? ↗
 
Via Benzinga
News headline image
8 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
LabCorp's Stock Soars After Q2 Performance, Analyst Highlights Strong Position In Healthcare Sector ↗
LabCorp reported Q2 2024 adjusted EPS of $3.94, surpassing expectations of $3.78. Sales increased by 6.2% to $3.22 billion, driven by organic revenue growth and acquisitions. LabCorp revised its 2024... 
Via Benzinga
News headline image
Quest Diagnostics' Q2 Earnings Performance Suggests Stable Stock, Modest Growth Ahead, Analyst Says ↗
Quest Diagnostics reported a second-quarter adjusted EPS of $2.35, surpassing the consensus of $2.34. Sales rose 2.5% year-over-year to $2.39 billion. The company raised its fiscal year 2024 revenue... 
Via Benzinga
News headline image
DGX Stock Earnings: Quest Diagnostics Beats EPS, Beats Revenue for Q2 2024 ↗
DGX stock results show that Quest Diagnostics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
US Stock Futures Little Changed As Traders Brace For Q2 Reports From Alphabet, Tesla: 'There Remains Strong Fundamental Support For Large Caps,' Says Economist ↗
The market mood turned jittery after Monday’s rebound, with index futures trading on either side of the unchanged line early Tuesday. The apprehensions reflect uncertainties regarding geopolitics,... 
Via Benzinga
Topics Artificial Intelligence
News headline image
Small-Cap Gains Resume Ahead Of Major Tech Earnings; UPS Faces Worst Day Ever, Bitcoin Dips Below $66,000: What's Driving Markets Tuesday? ↗
Tuesday's Wall Street session was mixed, with small-caps outperforming large-caps as investors awaited earnings from Alphabet Inc. and Tesla Inc. 
Via Benzinga
News headline image
Haystack Oncology and Lisata Therapeutics Initiate Research Collaboration to Use the Haystack MRD™ Technology to Evaluate Efficacy of Pancreatic Cancer Therapy
From Lisata Therapeutics, Inc.; Quest Diagnostics, Haystack Oncology
Via GlobeNewswire
News headline image
Peering Into Quest Diagnostics's Recent Short Interest ↗
 
Via Benzinga
News headline image
Analyst Scoreboard: 7 Ratings For Quest Diagnostics ↗
 
Via Benzinga
News headline image
How Is The Market Feeling About Quest Diagnostics? ↗
 
Via Benzinga
News headline image
Tesla, Alphabet, GM, Ford Lead Earnings Parade This Week As Market Struggles To Sustain The Summer Rally ↗
The earnings parade continues this week with a slightly accelerated tempo as analysts brace for a healthy reporting season. 
Via Benzinga
News headline image
Will Earnings Cheer Continue To Buoy Markets? Apple, Amazon, Pfizer, Coinbase Lead Flurry Of Q1 Reports This Week ↗
With the earnings season now halfway through, the percentage of S&P 500 companies reporting positive earnings surprises and the magnitude of earnings surprises were above their 10-year averages. 
Via Benzinga
Topics Stocks
News headline image
Peering Into Quest Diagnostics's Recent Short Interest ↗
 
Via Benzinga
News headline image
EXCLUSIVE: Haystack Oncology Inks Research Collaboration With Lisata Therapeutics To Use Haystack MRD Technology To Evaluate Pancreatic Cancer Therapy Efficacy ↗
Haystack Oncology, a Quest Diagnostics company, and Lisata Therapeutics collaborate to use Haystack MRD technology in a study of certepetide plus chemotherapy for metastatic pancreatic cancer, focusing... 
Via Benzinga
News headline image
S&P Global To Rally More Than 13%? Here Are 10 Top Analyst Forecasts For Friday ↗
 
Via Benzinga
Topics Stocks
News headline image
Myriad Genetics Sees Stock Surge with Hereditary Cancer Tests
Myriad Genetics Inc. (NASDAQ: MYGN) is a leader in genetic testing and precision medicine. The company offers a wide variety of genetic tests including 
Via MarketBeat
News headline image
Employers Struggle with Drug Test Policies Amid Varying State Laws, Cheating on Drug Tests Reaches 30-Year High ↗
Cheating on drug tests among American workers has reached a 30-year high, with Quest Diagnostics Inc. reporting 31,000 tampered samples out of 5.5 million in 2023. The rise in synthetic urine use and... 
Via Benzinga
Topics Cannabis
News headline image
The Analyst Landscape: 5 Takes On Quest Diagnostics ↗
 
Via Benzinga
Intelligent Bio Solutions Screening Technologies Poised to Disrupt The Healthcare Sector: INBS, LH, ABT, DGX
Via AB Newswire
News headline image
Intelligent Bio Solutions’ Fingerprint Drug Screening Technology Poised For Massive Growth ↗
Intelligent Bio Solutions (Nasdaq: INBS) is a medical technology company developing and commercializing innovative, intelligent, rapid, noninvasive testing solutions. 
Via Talk Markets
News headline image
Quest Diagnostics Says Sales In Q1 Increased For The First Time Since The Height Of Pandemic ↗
Latest financial insights from Quest Diagnostics. Q1 results beat estimates with adjusted EPS of $2.04 and sales of $2.34 billion, showcasing nearly 6% base business revenue growth. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.